Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia to cure advanced ovarian cancer
10.3969/j.issn.1000-8179.20121537
- VernacularTitle:多西他赛联合腹腔热灌注化疗加热疗治疗晚期卵巢癌
- Author:
Xiuju LIANG
;
Huili CHU
;
Jun WANG
;
Jingwang BI
- Publication Type:Journal Article
- Keywords:
docetaxel;
advanced ovarian cancer;
intraperitoneal chemotherapy;
hyperthermia
- From:
Chinese Journal of Clinical Oncology
2013;(17):1051-1054
- CountryChina
- Language:Chinese
-
Abstract:
Objective:This study aimed to observe the curative effect and adverse reaction of docetaxel combined with intraperitoneal cisplatin chemotherapy and hyperthermia treatment of advanced ovarian cancer. Methods:A total of 83 patients with inoperable and recurrent advanced ovarian cancer were randomly divided into two groups:hyperthermia group and control group. The hyperthermia group consisted of 42 cases of docetaxel chemotherapy immediately treated with intraperitoneal cisplatin chemotherapy combined with abdominal local hyperthermia. The control group included 41 cases of docetaxel chemotherapy and intraperitoneal cisplatin chemotherapy treatment only. Results:The total efficiencies of the hyperthermia treatment group and the control group were 81%and 58.1%, respectively, which showed that the total efficiency significantly improved (P<0.05). The ascite control rates were 78.3%and 66.7%and CA125 decreased by 84.2%and 61.5%for the hyperthermia and control groups, respectively. The main adverse reactions were gastrointestinal reaction and bone marrow suppression. However, differences were not statistically significant. Conclusion:Docetaxel combined with cisplatin intraperitoneal perfusion hyperthermia significantly improved the curative effect on advanced ovarian cancer without increasing toxicity, which indicates that it is a treatment worth popularizing.
